Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 4/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277791 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL10423569 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL28238157 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL1425715 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL2961305 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL23301314 | 0.98 | MAPT (0.43) | MAPTFDPSGPR84FFAR1LMNA | |
| SCHEMBL7911220 | 0.95 | MAPT (0.43) | MAPTOPRM1FDPSGPR84CA1 | |
| SCHEMBL9395704 | 0.92 | MAPT (0.46) | MAPTOPRM1FDPSGPR84FFAR1 | |
| SCHEMBL2352899 | 0.92 | MAPT (0.46) | MAPTOPRM1FDPSGPR84FFAR1 | |
| SCHEMBL9714347 | 0.92 | MAPT (0.46) | MAPTOPRM1FDPSGPR84FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7311206-B1 | Quaternary ammonium compounds for froth flotation of silicates from an iron ore | AKZO NOBEL N.V. (NL) | 2007-12-25 | — | — | US | claimed |
| WO-2000062937-A1 | QUATERNARY AMMONIUM COMPOUNDS FOR FROTH FLOTATION OF SILICATES FROM AN IRON ORE | AKZO NOBEL NV (NL) | 2000-10-26 | — | — | WO | claimed |
| CN-115175967-B | Ionic liquids for stabilizing viscosity of silicate-based coatings | 巴斯夫欧洲公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4136065-B1 | HYDROGENATION OF L-SORBOSE | BASF SE (DE) | 2024-04-24 | — | — | EP | disclosed |
| EP-4341236-A1 | PROCESS FOR THE SYNTHESIS OF L-IDITOL AND RECYCLING OF THE CATALYST | BASF SE (DE) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355497-A | Process for synthesizing L-iditol and recycling catalyst | 巴斯夫欧洲公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| US-20230143448-A1 | HYDROGENATION OF L-SORBOSE | BASF SE (DE) | 2023-05-11 | — | — | US | disclosed |
| EP-4165155-A1 | A LAUNDRY CARE OR DISH CARE COMPOSITION COMPRISING A POLY ALPHA-1,6-GLUCAN ESTER | The Procter & Gamble Company (US) | 2023-04-19 | — | — | EP | disclosed |
| EP-4136065-A1 | HYDROGENATION OF L-SORBOSE | BASF SE (DE) | 2023-02-22 | — | — | EP | disclosed |
| US-20230042328-A1 | IONIC LIQUID FOR STABILIZING VISCOSITY OF SILICATE-BASED COATINGS | BASF SE (DE) | 2023-02-09 | — | — | US | disclosed |
| WO-2004026803-A1 | METHOD FOR PRODUCING DIALDEHYDES AND/OR ETHYLENICALLY UNSATURATED MONOALDEHYDES BY HYDROFORMYLATING ETHYLENICALLY UNSATURATED COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | disclosed |
| EP-1383777-A1 | LIGANDS FOR PNICOGEN CHELATE COMPLEXES WITH A METAL OF SUBGROUP VIII AND USE OF THE COMPLEXES AS CATALYSTS FOR HYDROFORMYLATION, CARBONYLATION, HYDROCYANATION OR HYDROGENATION | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-28 | — | — | EP | disclosed |
| WO-2003066642-A1 | PHOSPHORUS CHELATE COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-14 | — | — | WO | disclosed |
| WO-2002083695-A1 | LIGANDS FOR PNICOGEN CHELATE COMPLEXES WITH A METAL OF SUBGROUP VIII AND USE OF THE COMPLEXES AS CATALYSTS FOR HYDROFORMYLATION, CARBONYLATION, HYDROCYANATION OR HYDROGENATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2000062937-A1 | QUATERNARY AMMONIUM COMPOUNDS FOR FROTH FLOTATION OF SILICATES FROM AN IRON ORE | AKZO NOBEL NV (NL) | 2000-10-26 | — | — | WO | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143448-A1 | HYDROGENATION OF L-SORBOSE | LDHA, ALPL, MPI | MAPT 919/4885OPRM1 2889/4885FDPS 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.